Ge Healthcare Company Profile
What is the competitive landscape for GE HEALTHCARE
GE HEALTHCARE has fifty approved drugs.
There is one US patent protecting GE HEALTHCARE drugs.
Summary for Ge Healthcare
| US Patents: | 1 |
| Tradenames: | 57 |
| Ingredients: | 39 |
| NDAs: | 50 |
Drugs and US Patents for Ge Healthcare
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ge Healthcare | HYPAQUE | diatrizoate sodium | SOLUTION;ORAL, RECTAL | 011386-003 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Ge Healthcare | NEOSCAN | gallium citrate ga-67 | INJECTABLE;INJECTION | 017655-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Ge Healthcare | CLARISCAN | gadoterate meglumine | SOLUTION;INTRAVENOUS | 210016-002 | Nov 1, 2019 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Ge Healthcare | OMNIPAQUE 350 | iohexol | SOLUTION;INJECTION, ORAL | 018956-004 | Dec 26, 1985 | AP | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| Ge Healthcare | OMNIPAQUE 350 | iohexol | SOLUTION;INJECTION, ORAL | 020608-003 | Oct 24, 1995 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Ge Healthcare | FLUORINE F-18 | sodium fluoride f-18 | INJECTABLE;INTRAVENOUS | 017042-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Ge Healthcare
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ge Healthcare | ISOPAQUE 440 | calcium metrizoate; meglumine metrizoate; metrizoate magnesium; metrizoate sodium | INJECTABLE;INJECTION | 016847-001 | Approved Prior to Jan 1, 1982 | 3,476,802 | ⤷ Start Trial |
| Ge Healthcare | OMNIPAQUE 240 | iohexol | SOLUTION;INJECTION, ORAL, RECTAL | 018956-002 | Dec 26, 1985 | 4,250,113 | ⤷ Start Trial |
| Ge Healthcare | VISIPAQUE 270 | iodixanol | INJECTABLE;INJECTION | 020808-001 | Aug 29, 1997 | 5,366,722 | ⤷ Start Trial |
| Ge Healthcare | VISIPAQUE 270 | iodixanol | INJECTABLE;INJECTION | 020351-001 | Mar 22, 1996 | 4,396,597 | ⤷ Start Trial |
| Ge Healthcare | VISIPAQUE 270 | iodixanol | INJECTABLE;INJECTION | 020351-001 | Mar 22, 1996 | 5,366,722 | ⤷ Start Trial |
| Ge Healthcare | VISIPAQUE 320 | iodixanol | INJECTABLE;INJECTION | 020808-002 | Aug 29, 1997 | 4,396,597 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Ge Healthcare Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Russian Federation | 2010101935 | ⤷ Start Trial |
| Mexico | 2010002196 | ⤷ Start Trial |
| European Patent Office | 2182988 | ⤷ Start Trial |
| Denmark | 2182988 | ⤷ Start Trial |
| Russian Federation | 2475267 | ⤷ Start Trial |
| Australia | 2008292201 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Ge Healthcare Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 3752510 | 301356 | Netherlands | ⤷ Start Trial | PRODUCT NAME: VANZACAFTOR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, BIJ VOORKEUR EEN CALCIUMZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/25/1943 20250701 |
| 0720599 | 300689 | Netherlands | ⤷ Start Trial | PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ATORVASTATINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER ATORVASTATINE CALCIUM TRIHYDRATE; NATIONAL REGISTRATION NO/DATE: RVG114373-114376 20141027; FIRST REGISTRATION: FR 2014091200122 20140912 |
| 0720599 | CR 2014 00050 | Denmark | ⤷ Start Trial | PRODUCT NAME: EZETIMIBE AND ATORVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING ATORVASTATIN AS ATORVASTATIN CALCIUM TRIHYDRATE; REG. NO/DATE: DE/H/3895-3898/001-004/DC 20140910 |
| 1611115 | 122015000016 | Germany | ⤷ Start Trial | PRODUCT NAME: FLUTEMETAMOL (18F) ODER EIN PHARMAZEUTISCH UNBEDENKLICHES SALZ, HYDRAT ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/14/941 20140822 |
| 2957286 | 1990003-4 | Sweden | ⤷ Start Trial | PRODUCT NAME: PATIROMER SORBITEX CALCIUM; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/17/1179, 2017-07-21; PRV HAR I BESLUT DEN 16 JULI 2025 RAETTAT SKYDDSTIDEN I FOELJANDE TILLAEGGSSKYDD I ENLIGHET MED PMD:S BESLUT PMAE 7804/24: 1990003-4 2190008-9 |
| 3347352 | SPC/GB22/064 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: LENACAPAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR LENACAPAVIR SODIUM; REGISTERED: UK EU/1/22/1671(FOR NI) 20220819; UK MORE ON HISTORY TAB 20220819 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
